Effect of mitomycin C on higher order aberrations in low and moderate myopic (astigmatic) PRK

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT201008094537N1

Enrollment

128

Registered

2011-01-24

Start date

2010-10-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia. myopia

Interventions

Intervention 1: Mitomycin C dosage 0.02% one drop in the end of surgery. Intervention 2: Normal saline one drop in the end of surgery.

Treatment - Drugs

Placebo

Mitomycin C dosage 0.02% one drop in the end of surgery

Normal saline one drop in the end of surgery

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Myopia lower than 4 D (Spherical Eq), Astigmatism lower than 1.87 D Exclusion criteria: Previous eye surgery, Dry eye syndrome, HOA RMS more than 0.3 microns, Anisometropia more than 1.5 D syndrome

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Higher order aberration. Timepoint: 1 month and 6 months. Method of measurement: Wavefront aberrometry by Zywave.	—

Secondary

Measure	Time frame
Corneal hysteresis. Timepoint: 1 month and 6 months. Method of measurement: Ocular Response Analyzer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactS-Farzad Mohammadi

Eye Research Center, Farabi Eye Hospital

sfmohamm@razi.tums.ac.ir+98 21 5542 1007

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026